US 11833168
Compounds and methods for increasing STMN2 expression
granted A61KA61K31/7115A61K31/712
Quick answer
US patent 11833168 (Compounds and methods for increasing STMN2 expression) held by Ionis Pharmaceuticals, Inc. expires Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ionis Pharmaceuticals, Inc.
- Grant date
- Tue Dec 05 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 30 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61K, A61K31/7115, A61K31/712, A61K31/7125, A61P